Sunitinib Malate

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis. Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug. Features and Benefits

Sunitinib malate. Sunitinib malate is also being studied in the treatment of other types of cancer. More About Sunitinib Malate. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. MedlinePlus Information on Sunitinib Malate - A lay language summary of important information about this drug that may include the. Sunitinib malate 1 Product Result | Match Criteria: Product Name, Property, Description Find here Sunitinib Malate Capsules, Sunitinib Capsules manufacturers, suppliers & exporters in India. Get contact details & address of companies manufacturing and supplying Sunitinib Malate Capsules, Sunitinib Capsules across India. Sunitinib Malate is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.

See risks and benefits. Learn about SUTENT® (sunitinib malate) clinical trial results for the treatment of adult patients with advanced kidney cancer (RCC). Sunitinib Malate. Class: Antineoplastic Agents - Kinase Inhibitors - Receptor Tyrosine Kinase Inhibitors - Tyrosine Kinase Inhibitors VA Class: AN900 Chemical Name: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Molecular Formula: C 22 H 27 FN 4 O 2 CAS Number: 557795-19-4 Brands: Sutent. Sunitinib Malate是一种多靶点RTK抑制剂，作用于VEGFR2 (Flk-1)和 PDGFRβ，在无细胞试验中IC50分别为80 nM 和2 nM，也会抑制c-Kit的活性。Sunitinib Malate 可有效地抑制 Ire1α 的自身磷酸化。Sunitinib Malate 可增加 death receptor 和 线粒体依赖的凋亡 mitochondrial-dependent apoptosis。 sunitinib malate The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.

Sunitinib malate is a potent pan-VEGF-receptor inhibitor and neuroprotectant. Aamir Aziz, BS, is a clinical research coordinator with Sierra Eye Associates in Reno, Nevada. Majid Khan, BS, and Noah Shafi, BS, are medical students at University of Nevada, Reno School of Medicine. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J. A sunitinib 10 mg/mL oral suspension may also be prepared by mixing the contents of 3 sunitinib 50 mg capsules with 15 mL of a 1:1 mixture of an Ora-Sweet/Ora-Plus solution to yield a final concentration of 10 mg/mL. Sunitinib malate, also called sunitinib, is a novel, oral, multi-targeted , small molecule oxindole tyrosine kinase inhibitor which inhibits multiple receptor tyrosine kinases including platelet-derived growth factor receptor , vascular endothelial growth factor receptor 1, 2 and 3, c-KIT, FLT3 kinase, colony-stimulating factor 1 receptor and RET kinase [2][3] [4].

Page 1 SUNITINIB MALATE ORAL CHEMOTHERAPY EDUCATION Name of your medication Generic name — sunitinib malate (soo-NIH-tih-nib MA layt) Brand name — Sutent® (SOO-tent) Approved uses Sunitinib is used to treat patients with gastrointestinal stromal tumor (GIST), advanced renal cell carcinoma (RCC), and Sunitinib, also known as sutent or su-11248, belongs to the class of organic compounds known as indolines. Indolines are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2, 3-dihydroindole.Sunitinib is a drug which is used for the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease. Sunitinib malate salt was obtained from chemistry department at TODA Research & Engineering Company, Iran and was used without any purification. Standard of E and Z isomer mixture, sunitinib malate N-oxide and impurity B was purchased from TLC PharmaChem Inc., Canada. HPLC-grade methanol, dichloromethane, acetic Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation. - Mechanism of Action & Protocol.

See risks and benefits. Learn about the indications for SUTENT® (sunitinib malate) on the official patient website. Sunitinib malate (Sutent, SU11248) is a small-molecule receptor tyrosine kinase inhibitor that inhibits cellular signaling of multiple targets such as the platelet-derived growth factor receptors and the vascular endothelial growth factor receptors and is used in the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal. Sunitinib and its active metabolite are metabolised by cytochrome P450 3A4. Dose reductions should be considered if the patient is taking an inhibitor of this enzyme. The dose of sunitinib may need to be increased if an enzyme-inducing drug is prescribed. Patients taking sunitinib should not take St John's wort because of this interaction. The recommended dose of sunitinib malate for the adjuvant treatment of RCC is 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off for nine 6-week cycles.

Sunitinib Malate Chemical Structure CAS NO. 341031-54-7 Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).